Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Edwards Lifesciences

Thumbnail
November 17, 2020

Boston deadheads its Lotus

Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.

Thumbnail
September 03, 2020

Medtechs that book the most sales per employee face the greatest losses

Welcome to the calm before the Covid-19 storm.

Article image
Vantage logo
August 25, 2020

Orthopaedics companies’ nightmare quarter

The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.

Article image
Vantage logo
May 21, 2020

Covid-19 takes a toll on medtech’s first quarter

Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.

Article image
Vantage logo
February 19, 2020

A listless quarter for Medtronic

Medtronic has lined up a whole pipeline of new devices – and it will need them.

Article image
Vantage logo
February 17, 2020

Jenavalve ploughs on alone

Article image
Vantage logo
January 31, 2020

Abbott adds mitral valve replacement to repair

Article image
Vantage logo
January 06, 2020

Big cap medtechs see out the decade in style

The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.

Article image
Vantage logo
November 29, 2019

Meril Life Sciences comes late to aortic valves

The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?

Article image
Vantage logo
October 24, 2019

Diagnostics specialists win the US device approval race

The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.

Article image
Vantage logo
October 15, 2019

Admedus moves from one unlikely area to another

A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.